Continuous glucose monitoring market seen doubling by 2032

By AI, Created 10:20 AM UTC, May 25, 2026, /AGP/ – The global continuous glucose monitoring market is forecast to rise from about $13.45 billion in 2025 to nearly $27.59 billion by 2032, driven by higher diabetes prevalence, wearable tech adoption and broader reimbursement. The market report points to home monitoring, smartphone-connected devices and AI-enabled analytics as the biggest growth catalysts.

Why it matters: - Continuous glucose monitoring is becoming a core diabetes management tool because it replaces frequent finger-prick testing with real-time tracking. - The market’s projected growth reflects rising demand for remote, connected care as diabetes cases climb worldwide. - Broader use of CGM could improve glycemic control, reduce hypoglycemic events and support longer-term disease management.

What happened: - The global continuous glucose monitoring market was valued at about $13.45 billion in 2025. - The market is projected to reach nearly $27.59 billion by 2032. - The report projects a 10.81% compound annual growth rate from 2026 to 2032. - The analysis was published May 25, 2026 from Austin, Texas. - The report is available through a sample request and a full market description.

The details: - Sensors hold the largest share of the component market because they require recurring replacement and continue to improve in accuracy and longevity. - Home care settings are expected to dominate during the forecast period as patients prefer remote monitoring and self-management tools. - Smartphone-integrated CGM systems are seeing strong demand because they offer convenience, real-time alerts and data sharing with caregivers and clinicians. - Bluetooth-enabled, cloud-based and wearable CGM connectivity options are also part of the market segmentation. - The report identifies hospitals, diagnostic centers and specialty clinics as additional end-user segments. - North America leads the market because of high diabetes prevalence, strong healthcare infrastructure, favorable reimbursement and fast adoption of advanced technologies. - Europe is seeing strong adoption due to higher awareness, rising diabetes rates and supportive regulatory policies. - Asia-Pacific is expected to post the fastest growth, with China, India, Japan and South Korea driving demand.

Between the lines: - The report ties market expansion to the global rise in Type 1 and Type 2 diabetes, driven by sedentary lifestyles, obesity, poor diets and aging populations. - Technology is shifting CGM from a monitoring tool to a broader diabetes platform, with AI analytics, predictive alerts and automated insulin delivery integration. - Preventive health trends are broadening the audience beyond diagnosed patients to wellness-focused consumers watching metabolic health. - Reimbursement support and telehealth expansion are making CGM easier to adopt in routine care. - Geopolitical tensions, including the Israel-Iran conflict, could disrupt supply chains through semiconductor shortages, higher transport costs and raw material delays. - The report warns that regional instability could affect R&D collaboration, technology exports and investment activity, even as the long-term outlook remains positive.

What’s next: - Manufacturers are expected to keep investing in longer sensor life, smaller devices, better accuracy and tighter smartphone integration. - Non-invasive glucose monitoring is positioned as a major opportunity if needle-free systems advance successfully. - AI and predictive analytics are likely to play a larger role in insulin guidance and personalized diabetes management. - Emerging markets in Asia-Pacific, Latin America and the Middle East are expected to offer new growth as healthcare access and awareness improve. - Partnerships between medical device companies and wearable tech firms may push CGM into smartwatches and fitness trackers. - The competitive field remains centered on Dexcom, Abbott Laboratories, Medtronic, Senseonics Holdings, Roche, Ascensia Diabetes Care, Insulet Corporation and Tandem Diabetes Care. - The report says the market’s long-term growth remains strong through 2032 as diabetes care becomes more connected, personalized and preventive.

The bottom line: - CGM is moving from a niche diabetes tool to a mainstream digital health category, and the next wave of growth will come from wearables, AI and home-based care.